Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies
Sign Up to like & getrecommendations! Published in 2018 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics10020050
Abstract: Doxorubicin cardiotoxicity has led to the development of superior chemotherapeutic agents such as AD 198. However, depletion of healthy neutrophils and thrombocytes from AD 198 therapy must be limited. This can be done by the… read more here.
Keywords: system; development vitro; liposomal system; cd22 targeted ... See more keywords